BioCardia, Inc..
BCDA.US | Research and experimental development on natural sciences and engineering
BioCardia, Inc. is a biotechnology company focused on developing novel cell-based therapies for cardiovascular diseases. The company's lead product candidates include CardiAMP Cell Therapy System for the treatment of heart failure and ischemic heart disease. BioCardia utilizes a proprietary biothera...Show More
Better Health for All
50
BioCardia, Inc. is a biotechnology company entirely focused on developing novel cell-based therapies for cardiovascular diseases, including treatments for heart failure and ischemic heart disease.
1
This indicates that 100% of its principal goods and services are aimed at health improvement. The company's activities primarily revolve around research, development, and clinical testing of advanced medical therapies, meaning it generates no revenue from products with negative health outcomes.
2
As a company solely dedicated to developing these therapies, its entire R&D budget is allocated to health improvement, which constitutes over 25% of its capital allocation.
Fair Money & Economic Opportunity
0
No evidence available to assess BioCardia, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
BioCardia, Inc. has reported zero employment-related penalties since 2010.
1
Additionally, no regulatory actions, violations, fines, or compliance issues related to labor have been mentioned in the provided articles.
2
Fair Trade & Ethical Sourcing
0
No evidence available to assess BioCardia, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
The provided corporate governance information does not contain any quantitative data, financial data, regulatory actions, certifications, or comparisons to industry benchmarks.
1
There are no mentions of fines, violations, or compliance issues, making it impossible to assess the company's performance against the specified metrics.
2
Kind to Animals
-60
BioCardia, Inc. is initiating animal studies for preclinical pharmacology toxicology testing for its BCDA-03 therapy, and preclinical testing was completed for BCDA-04, indicating reliance on animal models.
1
The company used 14 female Yorkshire swine in a study where myocardial infarction was induced by occluding the coronary artery for 60 minutes, with euthanasia at week 4.
2
Animal care was conducted in accordance with the Laboratory Animal Welfare Act, Stanford University Administrative Panel on Laboratory Animal Care, and the “Guide for the Care and Use of Laboratory Animals.”
3
While the company adheres to these guidelines for conducting animal tests, no explicit policy on the strength, scope, or enforcement of animal testing, particularly regarding reduction or prohibition, is stated. There is no evidence that the company employs non-animal testing methods for product safety and efficacy.
No War, No Weapons
0
The provided article discusses general export controls on high-parameter flow cytometers, cell sorters, and liquid chromatography mass spectrometers, noting their potential for both civilian and military applications, particularly in AI systems for military purposes.
1
However, the article does not provide any specific information or data points related to BCDA.US's involvement with these technologies, its revenue from defense contracts, its R&D investments, sales to sanctioned regimes, peacebuilding initiatives, or any other activities relevant to the 'No War, No Weapons' ethical value. Therefore, no KPIs can be scored based on the evidence provided.
Planet-Friendly Business
0
No evidence available to assess BioCardia, Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
The provided articles focus on BioCardia's clinical trials, product development, and regulatory aspects, such as FDA Breakthrough designation and data freezes for the CardiAMP Heart Failure Trial.
1
No information is available regarding the company's formal partnerships with community groups, local reinvestment, cultural impact assessments, local employment, grievance mechanisms, or any other metrics related to Respect for Cultures & Communities.
Safe & Smart Tech
0
No relevant evidence was found in the provided articles to assess BioCardia, Inc. (BCDA.US) against the 'Safe & Smart Tech' ethical value. The articles either contained financial data without security-related metrics or were privacy policies pertaining to a different entity (Biocartis), not BioCardia, Inc.
1
Zero Waste & Sustainable Products
0
No evidence available to assess BioCardia, Inc. on Zero Waste & Sustainable Products.